ArticleCell reports. Medicine2025

RANKL/PD-1 dual blockade demonstrates survival benefit for patients with advanced lung adenocarcinoma harboring KRAS mutations.

Hong-Shuai Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.